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Abstract
Recent studies show that regulatory T cells (Tregs) play an essential role in tolerance induction after organ transplantation.
In order to examine whether there are differences in the composition of the total CD4
+CD127
low+/2FoxP3
+- Treg cell pool
between stable transplant patients and patients with biopsy proven rejection (BPR), we compared the percentages and the
functional activity of the different Treg cell subsets (DR
high+CD45RA
2-Tregs, DR
low+CD45RA
2-Tregs, DR
2CD45RA
2-Tregs,
DR
2CD45RA
+-Tregs). All parameters were determined during the three different periods of time after transplantation (0–30
days, 31–1,000 days, .1,000 days). Among 156 transplant patients, 37 patients suffered from BPR. The most prominent
differences between rejecting and non-rejecting patients were observed regarding the DR
high+CD45RA
2-Treg cell subset.
Our data demonstrate that the suppressive activity of the total Treg pool strongly depends on the presence of these Treg
cells. Their percentage within the total Treg pool strongly decreased after transplantation and remained relatively low
during the first year after transplantation in all patients. Subsequently, the proportion of this Treg subset increased again in
patients who accepted the transplant and reached a value of healthy non-transplanted subjects. By contrast, in patients
with acute kidney rejection, the DR
high+CD45RA
2-Treg subset disappeared excessively, causing a reduction in the
suppressive activity of the total Treg pool. Therefore, both the monitoring of its percentage within the total Treg pool and
the monitoring of the HLA-DR MFI of the DR
+CD45RA
2-Treg subset may be useful tools for the prediction of graft rejection.
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Introduction
Despite the significant improvement in the understanding of
allo-immune mechanisms for graft failure and the development of
innovative immune-suppressants, graft and patient survival have
not increased as expected in the past decade. Prevention of graft
rejection and induction of tolerance are common goals in the field
of transplantation. Acute rejection has been shown to be one of the
strongest negative prognostic factors for long-term graft survival
after kidney transplantation [1,2]. The frequency of acute rejection
episodes is highest during the first 6 months after transplantation
[3]. During the second and third year post surgery, renal function
becomes stable and the incidence of acute rejection and graft loss
is markedly reduced [4]. After more than three years, only small
changes can be observed in regard to mean GFR decline, annual
incidence of graft loss and death, which all were found to represent
about 1%. Currently, only limited data exist which could explain
this phenomenon. Possibly, several transplant patients can develop
tolerance towards the foreign allo-antigens with advancing time
after transplantation.
Recent studies show that regulatory T cells (Tregs) play an
essential role in tolerance induction after organ transplantation
[5,6]. The majority of such studies were done using animal
models. However, in humans, the true function of Tregs in allo-
immunity remains in question [7,8]. Currently, Treg cells are
broadly subdivided into those that develop in the thymus (natural
(n) Tregs) and those that develop from conventional T-cells in the
periphery (induced (i) Tregs) [9]. A specific cell marker that
differentiates human nTregs from iTregs is not yet known. Both
Treg populations potentially suppress the proliferation of T
effector- cells [9] and are characterized by simultaneous expression
of the interleukin (IL) 2 receptor a chain (CD25) and the forkhead
box P3 (FoxP3) transcription factor [10]. In addition, an inverse
correlation between the expression of the IL-7 receptor a chain
(CD127) and their suppressive function was observed for
CD4
+CD25
+ FoxP3
+-Treg cells [11,12]. Currently, it is not
known, to which extent each of these Treg populations contributes
to the prevention of allograft rejection after transplantation.
However, there is a growing body of evidence that the suppressive
potency of the total Treg cell pool may depend on its composition
with distinct Treg subsets. Baecher-Allan et al. have characterized
a highly suppressive subset of Treg cells expressing HLA-class II
(DR) antigens [13]. Such HLA-DR
+- Tregs were shown to express
higher levels of FoxP3 and induced a more intense and a more
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34208rapid T cell suppression than the Tregs that lack HLA-DR
expression [13]. Moreover, it is known that the total Treg pool
contains a population of naı ¨ve CD45RA
+-Treg cells. Its
proportion decreases with increasing age and it was shown that
naı ¨ve CD45RA
+-Treg cells were less proliferative than their
CD45RO
+ counterparts [14]. Recent data demonstrate that the
suppressive activity of naı ¨ve CD45RA
+-Treg cells is impaired in
multiple sclerosis (MS) patients, suggesting that this Treg
population may potentially be involved in the pathology of
autoimmune diseases [15,16].
In the present study, we demonstrate that DR
high+CD45RA
2-
Tregs potentially affect the suppressive activity of the total Treg
pool and that the disappearance of this Treg subset gives a strong
indication for acute rejection processes.
Results
The percentage of CD4
+CD127
low+/2FoxP3
+-Tregs within
CD4
+-T cells is significantly decreased in kidney
transplant patients compared to non-transplanted
healthy volunteers
Both the percentage of CD4
+CD127
low+/2FoxP3
+-Treg cells of
CD4
+-T cells and their composition with four distinct Treg cell
subsets were determined in the circulation of healthy non-
transplanted volunteers (Group A), stable kidney transplant
patients (Group B) and kidney transplant patients with biopsy
proven rejection (BPR) (Group C), (Table 1, Figure 1). PBMCs
obtained from each participant were stained with anti-CD4, anti-
CD127, anti-FoxP3, anti-HLA-DR and anti-CD45RA monoclo-
nal antibodies and analyzed by five color flow cytometric analysis.
Figure 2 depicts the gating strategy for these measurements. First,
PBMCs were analyzed by fluorescence intensity of CD4 versus
side light scatter (SSC), (Figure 2A). The CD4
+-T cells (P1) were
gated and analyzed by fluorescence intensity of FoxP3 versus
CD127, (Figure 2B). The CD4
+CD127
low+/2FoxP3
+-Tregs were
gated (P2) and analyzed by their expression of HLA-DR versus
CD45RA (Fig. 2C). By that, three distinct Treg cell subsets
became apparent: DR
+CD45RA
2-Tregs (P3), DR
2CD45RA
2-
Tregs (P4) and naı ¨ve DR
2CD45RA
+-Tregs (P5). The percentages
of these distinct Treg subsets within the total CD4
+CD127
low+/2
FoxP3
+-Treg cell pool were estimated for all participants. In
addition, the level of HLA-DR expression (HLA-DR MFI) of the
DR
+CD45RA
2-Treg subset (Fig. 2C, P3) and the percentages of
DR
low+CD45RA
2-Tregs (Fig. 2D, P6) and DR
high+CD45RA
2-
Tregs (Fig. 2D, P7) of the total Treg cell pool (P2) were
documented.
Figure 3 shows the percentages of CD4
+CD127
low+/2FoxP3
+-
Treg cells within the total CD4
+-T cell pool in healthy non-
transplanted volunteers (Group A), in stable kidney transplant
patients (Group B) and in transplant patients with biopsy proven
rejection (BPR) (Group C). Compared to healthy non-transplanted
volunteers, the percentage of CD4
+CD127
low+/2FoxP3
+-Tregs
decreased continuously after transplantation. Significant differ-
ences concerning the percentage of CD4
+CD127
low+/2FoxP3
+-
Tregs at different time points (G1–G3) after transplantation
between rejecting and non-rejecting patients were not detected.
The suppressive activity of the CD4
+CD127
low+/2CD25
+-
Treg cell pool is significantly reduced in patients with
biopsy proven rejection (BPR)
To examine whether there were differences in the suppressive
activity of the total Treg pool between rejecting and non-rejecting
transplant patients we used coculture suppression assays described
in the methods section. To evaluate the suppressive capacity of
CD4
+CD127
low+/2CD25
+-Tregs, obtained from the different
patient groups (Group A–C), we determined the maximum
suppressive activity (ratio of Treg cells to responder T (Tresp)
cells 1:1) and calculated the ratio of Treg cells to Tresp cells that
resulted in a suppression of at least 15%. Figure 4A depicts the
results of one representative experiment obtained for healthy non-
transplanted volunteers (Group A), stable kidney transplant
patients (Group B) and transplant patients with BPR (Group C),
respectively. Figure 4B and 4C summarize the data for the
individual participants in each of these three patient groups. We
found that the suppressive activity of the isolated
CD4
+CD127
low+/2CD25
+-Tregs, obtained from stable transplant
recipients, was in the same range as that of CD4
+CD127
low+/2
CD25
+-Tregs obtained from healthy non-transplanted volunteers.
In contrast, the suppressive activity of Tregs obtained from
patients with acute rejection was significantly reduced compared
to healthy non-transplanted controls and to stable transplant
patients, (Figure 4B). Furthermore, the ratio of Treg cells to
responder cells (Titer Treg/Tresp) leading to a suppression of at
least 15%, was significantly decreased in patients with acute
rejection compared to healthy controls and stable transplant
patients (Figure 4C).
After transplantation, the composition of the total Treg
cell pool changes characteristically
In order to examine whether there were changes in the
composition of the total Treg cell pool with distinct Treg subsets
(DR
high+CD45RA
2-Tregs, DR
low+CD45RA
2-Tregs,
DR
2CD45RA
2-Tregs and naı ¨ve DR
2CD45RA
+-Tregs), we
determined their percentages in healthy controls and stable
transplant patients. Figures 5A-4D summarize the results of these
analyses. The individual ratios of the four Treg subsets showed
characteristic changes over time in transplanted patients. There-
fore, the transplant patients were grouped depending on the
period of time after surgery (G1: 0–30 days, G2: 31–1000 days,
G3: .1000 days). Non-transplanted volunteers served as healthy
controls (Group A). Compared to healthy non-transplanted
controls (Group A), the percentage of DR
high+CD45RA
2-Tregs
decreased strongly within the first 30 days after transplantation
(Fig. 5A, G1) and remained at minimum levels up to 1000 days
post surgery (Fig. 5A, (G2)). The percentage of DR
low+CD45RA
2-
Tregs increased initially (Fig. 5B, G1), but decreased subsequently
and reached the lowest levels between 31 and 1000 days post
transplantation (Fig. 5B, (G2)). After a period of 1000 days (G3)
both the percentages of DR
high+CD45RA
2-Tregs and DR
low+C-
D45RA
2-Tregs returned to levels in the range of healthy non-
transplanted controls (Group A), (Figures 5A and 5B). As the
differentiation between DR
high+CD45RA
2-Tregs and DR
low+C-
D45RA
2-Tregs was difficult, we additionally estimated the HLA-
DR mean fluorescence intensity (MFI) of the DR
+CD45RA
2-
Treg cell subset for all participants (Fig. 5E). We found a dramatic
decrease within the first days after surgery (Fig. 5E, G1), it is likely
due to a strong decrease of the DR
high+CD45RA
2-Treg subset
and an increase of the DR
low+CD45RA
2-Treg subset. However,
subsequently a continuous increase of the HLA-DR MFI could be
documented (Fig. 5E, G2–G3), because in the period between 30–
1000 days post surgery (Fig. 4E, G2), the percentage of the
DR
low+CD45RA
2-Treg subset decreased while the percentage of
DR
high+CD45RA
2-Treg subset did not change. After 1000 days
post surgery (Fig. 5E, G3), both the percentages of the
DR
high+CD45RA
2- and the DR
low+CD45RA
2-Treg subsets
increased strongly.
DR
high+CD45RA
2-Tregs in Renal Transplantation
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2CD45RA
+ -Treg subset
decreased significantly during the first 30 days after transplanta-
tion (Fig. 5C, G1), but afterwards, it increased strongly and
reached maximum levels between 31 and 1000 days post surgery
(Fig. 5C, G2). After 1000 days post surgery, a significant decrease
of this Treg subset was observed (Fig. 5C, G3).
The percentage of the DR
2CD45RA
2-Treg subset increased
immediately after transplantation (Fig. 5D, G1) and revealed the
highest levels between 31 and 1000 days after surgery (Fig. 5D,
G2). After more than 1000 days post transplantation (Fig. 5D, G3),
a slight but significant decrease was observed.
The percentage of the DR
high+CD45RA
2-Treg subset
within the total Treg pool and the HLA-DR MFI of the
DR
+CD45RA
2-Treg subset are strongly reduced in
patients with BPR after 31 days post surgery
In order to examine whether there are differences in the
composition of the total Treg cell pool between stable transplant
patients (Group B) and patients with BPR (Group C), we
compared the percentages of the different Treg cell subsets
(DR
high+CD45RA
2-Tregs, DR
low+CD45RA
2-Tregs, DR
2CD45-
RA
2-Tregs, DR
2CD45RA
+-Tregs) and the HLA-DR MFI of the
DR
+CD45RA
2-Treg cell subset. All parameters were determined
during the three different periods of time after transplantation (G1:
0–30 days, G2: 31–1000 days, G3: .1000 days). Figure 5A–5E
and Table 2 show the results of these measurements.
Among 156 transplant patients, 37 patients suffered from BPR.
The most prominent differences between non-rejecting (Group B)
and rejecting BPR patients (Group C) were seen regarding the
DR
high+CD45RA
2-Treg cell subset. BPR patients showed a 32%
reduction of this Treg subset within the total Treg cell pool after
31–1000 days (G2) and a 44% reduction after more than 1000
days post surgery (G3) versus patients without rejection. Differ-
ences concerning the DR
low+CD45RA
2-Treg subset could not be
detected. In parallel, the HLA-DR MFI of the DR
+CD45RA
2-
Treg cell subset was strongly reduced in patients with BPR versus
no BPR (31% after 31–1000 days (G2); 38% after 1000 days (G3)).
Figure 4E shows the relationship of the HLA-DR MFI of the
DR
+CD45RA
2-Treg cell subset and the time after transplantation
for stable transplant patients (Group B) and for patients with BPR
(Group C). A positive linear correlation was found for stable
transplant patients (r=0.569, p,0.00001) and for patients with
BPR (r=0.664, p,0.00001). Comparison of these two regression
lines revealed significant differences (p,0.001) between rejecting
and non-rejecting transplant patients.
Moreover, contrary to stable transplant patients, BPR patients
revealed a significantly higher proportion of DR
2CD45RA
2-
Tregs after 30 days post surgery. Their percentage within the total
Treg cell pool was 21% higher after 31 days (G2) and 39% higher
after 1000 days post transplantation (G3). The percentage of the
naı ¨ve DR
2CD45RA
+-Treg subset was lower in patients with BPR
after 30 days post surgery, compared to patients with stable
transplant function (G2 and G3). With regard to all examined
parameters, there were no differences between rejecting and non-
rejecting transplant patients during the first 30 days after surgery
(G1).
Figure 1. Flow diagram of the different patient groups.
doi:10.1371/journal.pone.0034208.g001
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+CD127
low+/2CD25
+-
Tregs observed in BPR patients correlates with a decline
of the HLA-DR MFI of the DR
+CD45RA
2-Treg subset
We examined whether there was a correlation between the
HLA-DR MFI of the DR
+CD45RA
2-Treg subset and the
suppressive activity of the total Treg cell pool. Figure 6 shows
the positive correlation (r=0.546, p,0.001) between the HLA-
DR MFI of the DR
+CD45RA
2-Treg subset and the titer (Treg/
Tresp) of Tregs, with which a minimum suppressive activity of
15% was achieved. Thereby, CD4
+CD127
low+/2CD25
+-Tregs
were obtained from healthy controls, BPR patients and patients
without BPR. In summary, our data clearly demonstrate that the
low suppressive activity of CD4
+CD127
low+/2CD25
+-Tregs ob-
served in BPR patients correlates with a low HLA-DR MFI of the
DR
+CD45RA
2-Treg cells subset. Otherwise, the high suppressive
activity assessed in healthy controls and stable transplant patients
correlate with a high HLA-DR MFI of the DR
+CD45RA
2-Treg
subset.
The DR
high+CD45RA
2-Treg subset has the highest
suppressive capacity within the total
CD4
+CD127
low+CD25
+-Treg cell pool
Our data demonstrate that the level of HLA-DR expression of
the DR
+CD45RA
2-Treg cell subset correlated positively with the
suppressive activity of the total Treg cell pool from healthy
controls, stable transplant patients and patients with BPR,
respectively. These findings suggested that the DR
high+C-
D45RA
2-Treg subset has the highest suppressive activity within
the total Treg cell pool. Thus, magnetically isolated
CD4
+CD127
low+/2CD25
+-Treg cells were separated via FACSort
into four different Treg cell subsets consisting of DR
high+C-
D45RA
2-, DR
low+CD45RA
2-, DR
2CD45RA
2- and naı ¨ve
DR
2CD45RA
+-Treg cells (Figure 7A). Subsequently, the sup-
pressive activity of these different Treg subsets was analyzed. Both
the maximum suppressive activity (Figure 7B) and the titer (Treg/
Tresp) with which a minimum suppressive activity of 15% could
be achieved (Figure 7C) were highest for the DR
high+CD45RA
2-
Treg subset. For the DR
low+CD45RA
2-Treg subset, the suppres-
sive activity was slightly reduced compared to the DR
high+C-
D45RA
2-Treg subset. An even less suppressive activity was found
for the DR
2CD45RA
2-Tregs and the lowest suppressive activity
was assessed for the naı ¨ve DR
2CD45RA
2-Treg subset. Thus, the
DR
high+CD45RA
2-Treg subset was shown to exhibit the highest
suppressive activity of the total CD4
+CD127
low+/2CD25
+-Treg
cell pool.
Discussion
Therefore, Tregs play an important role in transplantation
[5,17] and pregnancy [18,19], but also influence infectious diseases
[20], autoimmunity [21], and anti-tumor immunity [22]. Mean-
while, promising data in regard to solid organ transplantation are
increasingly available. Considering the potential role of Tregs in
Figure 2. Gating strategy for five color flow cytometric detection of the total CD4
+CD127
low+/2FoxP3
+-Treg cell pool and its
composition with four different Treg-subsets. A: CD4
+-T cells (P1) were gated by fluorescence intensity of CD4 versus side light scatter (SSC). B:
CD4
+CD127
low+/2FoxP3
+-Treg cells were gated by fluorescence intensity of FoxP3 versus CD127 (P2). C–D: The percentage of the DR
high+CD45RA
2-
(P6), the DR
low+CD45RA
2- (P7), the DR
2CD45RA
2- (P4) and the naı ¨ve DR
2CD45RA
+- (P5) Treg subset was estimated by analyzing CD4
+CD127
low+/2
CD25
+Foxp3
+-Treg cells (P2) for their expression of HLA-DR and CD45RA. In addition, the MFI of HLA-DR expression of the DR
+CD45RA
2FoxP3
+-Treg
subset (P3) was estimated for all participants. MFI=mean fluorescence intensity.
doi:10.1371/journal.pone.0034208.g002
DR
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aims of this study was to examine whether quantitative and
functional monitoring of Tregs could be used as markers of
immunological tolerance. We demonstrated that in post-transplant
patients the proportion of CD4
+CD127
low+/2FoxP3
+-Tregs de-
creased continuously in comparison to healthy volunteers over an
Table 1. Clinical characteristics of kidney transplant patients.
Group n
Median time after
Transplantation [days] Median Creatinine [mg/dl] Results of Biopsy Immunosuppression
A 2 0 - ---
B 119 181 [5–9155] 1.84 [0.74–11.6] no rejection
27 Tac+MPA+steroids
80 CsA+MPA+steroids
5 mTor+MPA+steroids
4 mTor+CsA+MPA+steroids
3 others+MPA+steroids
C 37 793 [6–6938] 2.41 [1.34–6.93] acute rejection
32 borderline rejections
8T a c +MPA+steroids
22 CsA+MPA+steroids
1 mTor+CsA+MPA+steroids
1 Azathioprin+MPA+steroids
2 BANFF 1A rejections
1C s A +MPA+steroids
1 mTor+CsA+MPA+steroids
3 acute humoral rejections
1C s A +MPA+steroids
1 mTor+MPA+steroids
1 mTor+CsA+MPA+steroids
doi:10.1371/journal.pone.0034208.t001
Figure 3. Detection of the percentage of CD4
+CD127
low+/2FoxP3
+-Treg cells of total CD4
+-T cells in rejecting and non-rejecting
patients after kidney transplantation. The percentage of CD4
+CD127
low+/2FoxP3
+-Tregs of total CD4
+-T cells was estimated in healthy non-
transplanted volunteers (m), in kidney transplant patients with stable transplant function (¤) and in kidney transplant patients with biopsy proven
rejection (BPR), (N). The percentage of CD4
+CD127
low+/2FoxP3
+-Tregs decreased continuously after transplantation. Significant differences between
rejecting and non-rejecting patients were not detected.
doi:10.1371/journal.pone.0034208.g003
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contrast to the results obtained with smaller studies [23,24,25], we
demonstrated in our cohort that the percentage of
CD4
+CD127
low+/2FoxP3
+-Tregs within the CD4
+-T cells was
not different between rejecting and non-rejecting patients. Such
differences may be based on inconsistent characterization of the
total Treg pool, different gating strategies and small numbers of
participants in many studies.
In addition, we demonstrated that the suppressive activity of the
total CD4
+CD127
low+/2CD25
+-Treg cell pool from patients with
biopsy proven rejection (BPR) was significantly reduced compared
to patients with stable graft function and compared to healthy non-
transplanted volunteers. Currently, limited data exist concerning
the suppressive activity of Tregs from transplant patients with
BPR. Dijke et al. demonstrated that CD4
+CD25
+FoxP3
+ Tregs of
heart transplant patients who experienced acute rejection had a
reduced regulatory function compared to those obtained from
non-rejecting patients [26]. These and our results are contrary to
the findings of a smaller study performed by Kreijveld et al. who
did not find any differences concerning the suppressive activity
between renal transplant recipients with rejection and those
without rejection [27].
Moreover, recent data revealed that the total Treg pool seems
to be inconsistent. Different Treg subsets such as naı ¨ve CD45RA
+-
or HLA-DR
+- expressing Treg cells were shown to be important
for the functional activity of the total Treg cell pool [13,15]. We
demonstrated that differential expression of HLA-DR and
CD45RA distinguished four different Treg subsets, which showed
characteristic changes concerning their percentages within the
total Treg pool during the time after transplantation. Initially after
transplantation, the proportion of the naı ¨ve DR
2CD45RA
+- and
the DR
high+CD45RA
2-Tregs decreased strongly while the pro-
portion of the DR
low+CD45RA
2- and the DR
2CD45RA
2-Tregs
showed a considerable increase. In consequence, the HLA-DR
MFI of the DR
+CD45RA
2-Treg subset was also dramatically
reduced. Such findings may propose that there is a strong
conversion of naı ¨ve Tregs into DR
2CD45RA
2- and DR
low+C-
D45RA
2-Tregs shortly after transplantation. In addition, we
Figure 4. Evaluation of the suppressive activity of CD4
+CD127
low+/2CD25
+-Treg cells obtained from healthy non-transplanted
volunteers and kidney transplant patients with stable transplant function or acute rejection. A: CD4
+CD127
low+/2CD25
+-Treg cells were
isolated by the MACS technique and their suppressive activity was examined using suppression assays (see methods). One representative experiment
is shown for healthy volunteers, kidney recipients with stable transplant function and kidney recipients with acute rejection. The maximum
suppressive activity (Treg/Tresp=1/1) (B) and the ratio of Treg/Tresp (titer) up to which the purified Treg cells could be diluted to achieve a minimum
suppressive activity of at least 15% (C), were estimated for all participants. The figures show the individual and median data obtained for all patients
groups.
doi:10.1371/journal.pone.0034208.g004
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+CD127
low+/2FoxP3
+-Treg cell pool with four different Treg
subsets during the time after transplantation. The percentage of the DR
high+CD45RA
2- (A), the DR
low+CD45RA
2- (B), the DR
2CD45RA
+- (C), and
the DR
2CD45RA
2- (D) Treg subset within the total Treg cell pool was estimated in healthy non-transplanted volunteers (m) and in non-rejecting (¤)
and rejecting kidney transplant patients (N) at different time points after transplantation. In addition the HLA-DR MFI of the DR
+CD45RA
2-Treg
subset was determined for all participants in all patient groups (E). Monitoring the HLA-DR MFI allowed a significant discrimination between rejecting
and non-rejecting patients, due to a significantly reduced percentage of the DR
high+CD45RA
2-Treg subset within the total Treg pool. MFI=mean
fluorescence intensity.
doi:10.1371/journal.pone.0034208.g005
Table 2. Percentage of different Treg subsets of the total Treg pool obtained from healthy non-transplanted volunteers and
kidney transplant patients in the presence or absence of BPR.
Time after Tx [days] n
DR
2CD45RA
+
[% Tregs]
DR
2CD45RA
2
[% Tregs]
DR
low+ CD45RA
2
[% Tregs]
DR
high+ CD45RA
2
[% Tregs] HLA-DR MFI
Controls 20 34 (17–61) 33 (19–45) 25 (14–33) 7.5 (4.5–20.1) 10470 (7607–15090)
No BPR 0–30 36 20 (5–50) 37 (21–59) 34 (14–53) 2.8 (0.5–9.6) 4604 (2112–9076)
31–1000 48 35 (13–62) 42 (27–65) 16 (5–29) 2.5 (0.4–7.8) 7431 (2782–16440)
.1000 35 24 (7–59) 33 (22–57) 28 (7–47) 8.4 (2.1–24.8) 11102 (7219–21025)
BPR 0–30 5 16 (10–30) 35 (30–45) 37 (30–47) 3.6 (2.0–4.3) 4058 (4002–4817)
31–1000 15 28 (12–47)* 51 (34–62)* 16 (9–27) 1.7 (1.0–2.8)* 5151 (3230–6401)*
.1000 17 21 (6–41) 46 (32–60)*** 26 (14–41) 4.7 (2.2–8.1)*** 6843 (5312–9105)***
*: p,0.05; no BPR versus BPR.
***: p,0.001; no BPR versus BPR.
doi:10.1371/journal.pone.0034208.t002
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2CD45RA
+-Treg
subset increased strongly during the first year but decreased
considerably during the time afterwards. Complementary to the
naı ¨ve DR
2CD45RA
+-Treg subset the DR
low+CD45RA
2-Treg
subset decreased significantly during the first year but increased
during the time afterwards. Such findings may propose that naı ¨ve
DR
2CD45RA
+-Treg cells may be increasingly released by the
thymus during the first year after transplantation. Presumably,
after that time, the thymic output of Treg cells is exhausted. As
HLA-DR
+-Treg cells are known to represent highly activated
mature Treg cells [13], it seems likely that during the first year
after transplantation such cells were preferentially eliminated,
presumably due to permanent allogenic stimulation of the immune
system. After that time, the maturation of the HLA-DR
+-Treg
cells outnumbers their elimination and the percentage of the HLA-
DR
+-Treg cells again increases to the level of healthy non-
transplanted volunteers. In either case it seems that the changes in
the percentages of the DR
high+- and DR
low+CD45RA
2-Treg cells
occur in the way that the HLA-DR MFI increases continuously
after transplantation. Such findings may explain why transplant
outcome studies have shown markedly reduced rejection rates
after three years post surgery [3,4].
To determine whether there were differences in the composition
of the total Treg cell pool between transplant patients with and
without BPR, we determined the proportion of the different Treg
cell subsets for both patient collectives. Comparable to previous
works [27], we found a reduction of the naı ¨ve DR
2CD45RA
+-
Treg subset in regard to the total Treg pool in patients with BPR
compared to patients with stable transplant function. Rejecting
patients showed significantly higher proportions of
DR
2CD45RA
2-Treg cells, but the most prominent difference
between rejecting and non-rejecting patients was seen regarding
the HLA-DR MFI of the DR
+CD45RA
2-Treg cell subset. This
effect may be explained by the fact that patients with allograft
rejection showed a highly significant decrease of the DR
high+C-
D45RA
2-Treg subset within the total Treg cell pool.
The evaluation of the suppressive activity of each of the four
different Treg subsets (DR
high+CD45RA
2-, DR
low+CD45RA
2-,
DR
2CD45RA
2- and DR
2CD45RA
+-Tregs) revealed that the
DR
high+CD45RA
2-Treg subset had the highest suppressive
activity compared to the other Treg subsets.
Similar to findings documented by Baecher-Allan [13], the
populations of DR
high+CD45RA
2-Tregs and DR
low+CD45RA
2-
Tregs had a higher suppressive capacity than the populations of
DR
2CD45RA
2- and DR
2CD45RA
+-Tregs. Therefore, specifi-
cally the loss of DR
high CD45RA
2-Tregs obviously impaired the
suppressive activity of the total Treg cell pool. Our data clearly
demonstrate that the determination of the HLA-DR MFI allows a
precise evaluation of the ratio between DR
high+CD45RA
2-Tregs
and DR
low+CD45RA
2-Tregs within the DR
+CD45RA
2-Treg cell
subset. We found a significant correlation between the level of
HLA-DR expression of the DR
+CD45RA
2-Treg subset and the
suppressive activity of the total Treg pool, determined both in
healthy non-transplanted volunteers, healthy transplanted patients
and transplanted patients with BPR. The lowest suppressive
activity of the CD4
+CD127
low+/2CD25
+-Treg pool which corre-
lated with a low HLA-DR MFI of the DR
+CD45RA
2-Treg cell
subset was observed in patients with BPR.
During pregnancy the ‘‘fetal semi-allograft’’ is perfectly
tolerated by the maternal immune system. In a recent published
study we demonstrated that women with preterm labor necessi-
tating preterm delivery showed significantly reduced HLA-DR
expression of CD4
+CD127
low+/2CD25
+FoxP3
+-Tregs, indicating
that the immunologic mechanisms leading to preterm labor may
be similar to those leading to allograft rejection after transplan-
tation [28]. The underrepresentation of HLA-DR
+-Treg cells in
the neonatal compared with the adult circulation indicates that the
presumed nTreg population gains HLA-DR expression upon
Figure 6. Correlation between the HLA-DR MFI of the DR
+CD45RA
2-Treg subset and the ratio of Treg/Tresp (titer) up to which a
significant suppression could be achieved. CD4
+CD127
low+/2CD25
+-Tregs were purified from healthy non-transplanted volunteers (m), kidney
transplant patients with stable transplant function (¤) and kidney transplant patients with BPR (N). Their suppressive activity concerning the ratio of
Treg/Tresp (titer) up to which the purified Treg cells could be diluted to achieve a minimum suppressive activity of at least 15% was related to the
HLA-DR MFI of the DR
+CD45RA
2-Treg subset. The figure shows the positive correlation (r=0.546, p,0.001) between the HLA-DR MFI of the
DR
+CD45RA
2-Treg subset and the ratio of Treg/Tresp (titer). MFI=mean fluorescence intensity.
doi:10.1371/journal.pone.0034208.g006
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lowDR
+-
Tregs are terminally differentiated effector Tregs, as they do not
proliferate and are highly sensitive to apoptosis [30]. It was shown
that Granzyme B, which was produced by strongly stimulated
non-regulatory responder CD4
+-T cells, reduced especially the
suppressive capacity of the non-proliferating HLA-DR
+-Tregs
cells [30]. On the other hand, the proliferation-competent HLA-
DR
2-Treg cells remained viable [30] and were shown to be more
sensitive to Fas-L induced apoptosis [31]. Therefore, it may be
hypothesized that the decrease in the MFI of the DR
+CD45RA
2-
Treg cell subset obtained from rejecting kidney recipients may be
caused by the increased Granzyme B induced apoptosis of
DR
+CD45RA
2-Treg cells which express the HLA-DR molecules
very strongly. As it was ascertained that the Granzyme B induced
apoptosis of the highly suppressive HLA-DR
+-Treg cells happened
preferentially in the case of strong responder T-cell stimulation
[30], it may be assumed that acute rejection episodes after
transplantation that are characterized by strong stimulation of
CD4
+-T cells lead to a loss of the strongly suppressive DR
high+-
Treg-subset.
In summary, we clearly demonstrated that patients with biopsy
proven rejection (BPR) show deficiencies concerning the function-
al activity of their Treg pool. Thereby, its composition was
changed in the way that the DR
high+CD45RA
2-Treg subset,
which was shown to possess the highest suppressive activity, was
decreased. In contrast, the DR
2CD45RA
2-Treg subset with
lower suppressive capacity was increased in transplanted patients
with acute rejection. Especially the determination of the HLA-DR
MFI of the DR
+CD45RA
2-Treg subset allowed a significant
discrimination between patients with acute graft rejection and
those without rejection. The clinical usefulness of the monitoring
of these peripheral blood parameters after solid organ transplan-
tation and its relation to clinical outcomes needs to be investigated
in large prospective cohort studies of transplant patients.
Materials and Methods
Study population
The study was approved by the Ethics Committee of the
Medical Faculty Heidelberg. All patients and healthy controls
were fully informed of the aim of the study and written informed
consent was obtained from all participants.
Figure 7. Positive selection and functional testing of four different Treg subsets within the total CD4
+CD127
low+/2CD25
+-Treg pool.
A: Magnetically isolated CD4
+CD127
low+/2CD25
+-Treg cells were stained with anti-HLA-DR and anti-CD45RA specific monoclonal antibodies and
sorted into a population of DR
high+CD45RA
2-, DR
low+CD45RA
2-, DR
2CD45RA
2-, and naı ¨ve DR
2CD45RA
+-Treg cells. Subsequently the different Treg
populations obtained from six different healthy non-transplanted volunteers were analyzed concerning their maximum suppressive activity (Treg/
Tresp=1/1) (B) and the minimum ratio of Treg/Tresp (titer) up to which the purified Tregs could be diluted to achieve a minimum suppressive activity
of at least 15% (C).
doi:10.1371/journal.pone.0034208.g007
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(Group A) and 156 kidney transplant patients (Groups B and C)
(Table 1). Forty-seven patients received a graft obtained from a
living donor and 109 patients received a graft from a cadaveric
donor. The mean age of our transplant cohort was 45 years (20–73
years). The causes of end-stage renal failure in our transplant
cohort were diabetes mellitus (38%, n=59), vascular nephopathy
(26%, n=41), glomerulonephritis (15%, n=23), autosomal
dominant polycystic kidney disease (8%, n=12), autoimmune
diseases (5%, n=8) like systemic lupus erythematosus and systemic
vasculitis and 8% (n=13) were unknown. Blood samples were
obtained on the same day when kidney transplant recipients
admitted to the Department of Nephrology for kidney biopsy.
Kidney biopsies were classified according to the BANFF-
classification [32,33]. Biopsy proven rejection was defined as
rising creatinine over 30% above the last three measurements and
further pathological findings according to the BANFF-classifica-
tion (Table 1). Patients with acute graft failure because of infection,
postrenal obstruction or drug induced renal failure were excluded.
All transplant patients were further subdivided into three different
groups. The first group (G1) contains transplant recipients before
the 30th day after transplantation. The second group (G2)
contains recipients between the 31st and the 1000th day after
transplantation and the third group (G3) contains recipients more
than 1000 days post transplantation. The 156 transplant patients
received an immunosuppressive regime with Mycophenolic acid
(MPA), Methylprednisolone and Calcineurininhibitors (Ciclos-
porin: 104 patients; Tacrolimus: 35 patients) or mTOR-Inhibitors
(Everolimus: 13 patients, whereas 7 recipients received a
combination of Cyclosporine and Everolimus) and 4 recipients
received other immunosuppressive drugs (Table 1).
Fluorescence-activated cell sorter (FACS) staining
Venous blood samples (9 ml) from all patients were collected
into EDTA-containing tubes. Whole peripheral blood mononu-
clear cells (PBMCs) were isolated by Ficoll-Hypaque (Amersham
Bioscience) gradient centrifugation and analyzed by five color flow
cytometric analysis. Briefly, PBMCs (4610
6 cells) were surface-
stained with 10 ml PerCP-conjugated-anti-CD4 (BD Bioscience),
10 ml PE-conjugated anti-CD127 (eBioscience), 5 ml PE-Cy7-
conjugated anti-HLA-DR (BD Bioscience) and 20 ml APC-
conjugated anti-CD45RA (BD Bioscience) mouse monoclonal
antibodies. Intracellular staining for the detection of FoxP3 was
achieved using a FITC labeled anti-human FoxP3 staining set
(clone PCH101, eBioscience) according to the manufacturer’s
instructions. Both the percentage of CD4
+CD127
low+/2FoxP3
+-
Treg cells of total CD4
+-T cells and the percentage of
DR
high+CD45RA
2-Tregs, DR
low+CD45RA
2-Tregs, DR
2CD45-
RA
2-Tregs and naı ¨ve DR
2CD45RA
+-Tregs within the total Treg
pool were estimated for all participants. In addition the mean
fluorescence intensity (MFI) of HLA-DR expression of the
DR
+CD45RA
2-Treg cell subset was estimated for all participants.
Negative control samples were incubated with isotype-matched
antibodies. Dead cells were excluded by forward and side scatter
characteristics. Cells were analyzed by a FACS Canto cytometer
(BD Bioscience). Cells were analyzed by a FACS Canto cytometer
(BD Bioscience) which is equipped with a 488-nm blue laser and a
633-nm red laser. The following standard filter set-ups were used:
PerCP: 655 Longpass/670 LP Bandpass; PE: 556 Longpass/585/
42 Bandpass; FITC: 502 Longpass/530/30 Bandpass; PE-Cy7:
735 Longpass/780/60 Bandpass; APC: 660/20 Bandpass).
Statistical analysis was based on at least 100,000 gated CD4
+-T
cells.
Positive selection and staining of
CD4
+CD127
low+/2CD25
+-Treg cells
Whole peripheral blood mononuclear cells (PBMCs) were
isolated from 45 ml EDTA-blood samples by Ficoll-Hypaque
(Amersham Bioscience) gradient centrifugation. The
CD4
+CD127
low+/2CD25
+-Treg cells were purified using the
CD4
+CD127
low+/2CD25
+-Regulatory T cell Isolation Kit II
(Miltenyi Biotec) according to the manufacturer’s instructions.
First CD4
+CD127
low+/2-T-cells were isolated by magnetic
depletion of non-CD4
+CD127
high+-T-cells. In a second step, the
CD4
+CD127
low+/2CD25
+-Treg cells were isolated by positive
selection over two consecutive columns. The CD4
+CD127
low+/2
CD25
2-T cells were obtained in the flow-through fraction and
used as responder T cells. The CD4
+CD127
low+/2CD25
+-Treg
cells were subsequently retrieved from the columns. The purified
CD4
+CD127
low+/2CD25
+-Treg cell fraction was analyzed using
four color flow cytometry. Briefly, 1610
5 cells were stained with
10 ml PerCP-conjugated-anti-CD4, PE-conjugated anti-CD25,
FITC-conjugated FoxP3 and biotin-conjugated anti-CD127
monoclonal antibodies. Positive staining for CD127 was detected
using APC-conjugated streptavidin molecules. On average, 85%
of the isolated CD4
+CD127
low+/2CD25
+-Treg cells were shown
to be within the CD4
+CD127
low+/2CD25
+Foxp3
+-Treg cell
population.
Co-culture suppression assay
Whole peripheral mononuclear cells (PBMCs) were isolated
from 45 ml peripheral blood drawn in EDTA tubes by Ficoll-
Hypaque (Amersham Bioscience) gradient centrifugation.
CD4
+CD127
low+/2CD25
+-Treg cells were purified using the
CD4
+CD127
low+/2CD25
+-Regulatory T cell Isolation Kit II
(Miltenyi Biotec) described above. In all assays, 2610
4 respond-
er-T-cells were co-cultured with the purified CD4
+CD127
low+/2
CD25
+-Treg cells at ratios 1:1 to 1:256 in 96-well v-bottom plates.
Suppression assays were performed in a final volume of 100 ml/
well of X-VIVO15 medium (Bio Whittaker). For T-cell stimula-
tion, the medium was supplemented with 1 mg/ml anti-CD3 and
2 mg/ml anti-CD28 antibodies (eBioscience). As controls,
CD4
+CD127
low+/2CD25
+-Treg cells and responder T cells alone
were cultured both with and without any stimulus. Cells were
incubated at 37uC and 5% of CO2. After four days, 1 mCi
3H-
thymidine was added to the cultures and cells were further
incubated for 16 hours. Then, cells were harvested and
3H
incorporation was measured by scintillation counting. All assays
exhibited ,10% SEM and were performed a minimum of six
times using blood from 6 different healthy non-transplanted
volunteers, 32 healthy non-rejecting transplant patients and 17
transplant patients with acute rejection. In order to compare the
suppressive capacity of the isolated CD4
+CD127
low+/2CD25
+-
Tregs between the different patient groups, we calculated the
maximum suppressive activity (ratio of Treg cells to responder T
cells 1:1) and the minimum ratio of Treg cells to responder cells,
with which a suppression of at least 15% could be achieved.
Sorting and functional testing of the four different Treg
cell subsets
Venous blood samples (100 ml) from six different healthy, non-
transplanted volunteers were collected into EDTA-containing
tubes. The whole peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll-Hypaque (Amersham Bioscience) gradient
centrifugation. For fluorescence activated cell sorting of the four
different Treg cell subsets, CD4
+CD127
low+/2CD25
+-Treg cells
were purified using the CD4
+CD127
low+/2CD25
+-Regulatory T
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Respectively, 5610
5 cells of the isolated CD4
+CD127
low+/2
CD25
+-Treg cells were stained with 15 ml PE-Cy7-conjugated
anti-HLA-DR (BD Bioscience) and 50 ml FITC-conjugated anti-
CD45RA mouse monoclonal antibodies. Dead cells were
excluded, while the remaining CD4
+CD127
low+/2CD25
+-Treg
cells were sorted using a FACS-VantageSE-Sorter (BD Biosci-
ence). Thereby, the CD4
+CD127
low+/2CD25
+-Treg cell popula-
tion was divided into four Treg subsets: DR
high+CD45RA
2-,
DR
low+CD45RA
2-, DR
2CD45RA
2-, and naı ¨ve DR
2CD45RA
+-
Treg cells. Subsequently, the suppressive activity of each Treg
population was analyzed using the above described suppression
assay.
Statistical analysis
Statistical comparison of the percentages of CD4
+CD127
low+/2
FoxP3
+-Treg cells of CD4
+-T cells, of the percentages of the
different Treg subsets (DR
high+CD45RA
2-Tregs, DR
low+C-
D45RA
2-Tregs, DR
2CD45RA
2-Tregs and naı ¨ve DR
2CD45-
RA
+-Tregs) within the total CD4
+CD127
low+/2FoxP3
+-Treg cell
pool and of the HLA-DR MFIs between the different patient
populations was done using the non-parametric H test of Kruskal
and Wallis, which is used for simultaneous comparison of more
than two sample populations. Each H test was followed by a Dunn
test. Comparison of the suppressive activity of the purified
CD4
+CD127
low+/2FoxP3
+-Tregs cells was also done using the
Kruskal-Wallis-Test. P,0.05 was considered significant. Statistical
analyses and graphs were performed using GraphPad Prism
version 5 (San Diego, CA, USA) and BiAS 9.14 for windows
(Frankfurt, Germany).
Acknowledgments
We would like to thank Dieter Stefan (Institute of Immunology,
Heidelberg, Germany) for professional help with FACS sorting of Treg
cell subsets.
Author Contributions
Conceived and designed the experiments: MS AS MZ. Performed the
experiments: NS FH. Analyzed the data: MS AS NS SM ES MZ.
Contributed reagents/materials/analysis tools: NS AS FH ES SM. Wrote
the paper: MS AS.
References
1. Tesi RJ, Elkhammas EA, Henry ML, Davies EA, Salazar A, et al. (1993) Acute
rejection episodes: best predictor of long-term primary cadaveric renal
transplant survival. Transplant Proc 25: 901–902.
2. Pirsch JD, Ploeg RJ, Gange S, D’Alessandro AM, Knechtle SJ, et al. (1996)
Determinants of graft survival after renal transplantation. Transplantation 61:
1581–1586.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B (2004) Lack of
improvement in renal allograft survival despite a marked decrease in acute
rejection rates over the most recent era. American journal of transplantation 4:
378–383.
4. Ekberg H, Bernasconi C, Tedesco-Silva H, Vitko S, Hugo C, et al. (2009)
Calcineurin inhibitor minimization in the Symphony study: observational results
3 years after transplantation. American journal of transplantation 9: 1876–1885.
5. Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, et al. (2008)
Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+
regulatory T lymphocytes. Nat Med 14: 88–92.
6. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, et al. (2007)
Regulatory T cells and T cell depletion: role of immunosuppressive drugs.
Journal of the American Society of Nephrology: JASN 18: 1007–1018.
7. Li XC, Turka LA (2010) An update on regulatory T cells in transplant tolerance
and rejection. Nature reviews Nephrology 6: 577–583.
8. Boros P, Bromberg JS (2009) Human FOXP3+ regulatory T cells in
transplantation. American journal of transplantation 9: 1719–1724.
9. Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+
regulatory T cells: more of the same or a division of labor? Immunity 30:
626–635.
10. Banham AH, Powrie FM, Suri-Payer E (2006) FOXP3+ regulatory T cells:
Current controversies and future perspectives. Eur J Immunol 36: 2832–2836.
11. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127
expression inversely correlates with FoxP3 and suppressive function of human
CD4+ T reg cells. The Journal of experimental medicine 203: 1701–1711.
12. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, et al.
(2006) Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 107:
2830–2838.
13. Baecher-Allan C, Wolf E, Hafler DA (2006) MHC class II expression identifies
functionally distinct human regulatory T cells. Journal of immunology 176:
4622–4631.
14. Booth NJ, McQuaid AJ, Sobande T, Kissane S, Agius E, et al. (2010) Different
proliferative potential and migratory characteristics of human CD4+ regulatory
T cells that express either CD45RA or CD45RO. Journal of immunology 184:
4317–4326.
15. Haas J, Fritzsching B, Trubswetter P, Korporal M, Milkova L, et al. (2007)
Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg
suppressive function and determines Treg dysfunction in multiple sclerosis.
Journal of immunology 179: 1322–1330.
16. Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, et al. (2008)
Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development
and function are disturbed in multiple sclerosis patients: recovery of memory
Treg homeostasis during disease progression. Journal of immunology 180:
6411–6420.
17. Lopez-Hoyos M, Segundo DS, Fernandez-Fresnedo G, Marin MJ, Gonzalez-
Martin V, et al. (2009) Regulatory T cells in renal transplantation and
modulation by immunosuppression. Transplantation 88: S31–39.
18. Steinborn A, Haensch GM, Mahnke K, Schmitt E, Toermer A, et al. (2008)
Distinct subsets of regulatory T cells during pregnancy: is the imbalance of these
subsets involved in the pathogenesis of preeclampsia? Clin Immunol 129:
401–412.
19. Aluvihare VR, Kallikourdis M, Betz AG (2004) Regulatory T cells mediate
maternal tolerance to the fetus. Nat Immunol 5: 266–271.
20. Rouse BT, Sarangi PP, Suvas S (2006) Regulatory T cells in virus infections.
Immunological reviews 212: 272–286.
21. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, et al. (2006) Foxp3+ CD25+
CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune
disease. Immunol Rev 212: 8–27.
22. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108: 804–811.
23. Stenard F, Nguyen C, Cox K, Kambham N, Umetsu DT, et al. (2009)
Decreases in circulating CD4+CD25hiFOXP3+ cells and increases in intragraft
FOXP3+ cells accompany allograft rejection in pediatric liver allograft
recipients. Pediatr Transplant 13: 70–80.
24. Louis S, Braudeau C, Giral M, Dupont A, Moizant F, et al. (2006) Contrasting
CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational
drug-free tolerance. Transplantation 81: 398–407.
25. Braudeau C, Racape M, Giral M, Louis S, Moreau A, et al. (2007) Variation in
numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory
properties in long-term graft outcome. Transpl Int 20: 845–855.
26. Dijke IE, Korevaar SS, Caliskan K, Balk AH, Maat AP, et al. (2009) Inadequate
immune regulatory function of CD4+CD25bright+FoxP3+ T cells in heart
transplant patients who experience acute cellular rejection. Transplantation 87:
1191–1200.
27. Kreijveld E, Koenen HJ, van Cranenbroek B, van Rijssen E, Joosten I, et al.
(2008) Immunological monitoring of renal transplant recipients to predict acute
allograft rejection following the discontinuation of tacrolimus. PloS one 3: e2711.
28. Kisielewicz A, Schaier M, Schmitt E, Hug F, Haensch GM, et al. (2010) A
distinct subset of HLA-DR+-regulatory T cells is involved in the induction of
preterm labor during pregnancy and in the induction of organ rejection after
transplantation. Clin Immunol 137: 209–220.
29. Baecher-Allan CM, Costantino CM, Cvetanovich GL, Ashley CW, Beriou G,
et al. (2011) CD2 costimulation reveals defective activity by human CD4+CD25
hi regulatory cells in patients with multiple sclerosis. Journal of immunology 186:
3317–3326.
30. Ashley CW, Baecher-Allan C (2009) Cutting Edge: Responder T cells regulate
human DR+ effector regulatory T cell activity via granzyme B. J Immunol 183:
4843–4847.
31. Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, et al. (2008) Apoptosis as a
mechanism of T-regulatory cell homeostasis and suppression. Immunology and
cell biology 86: 650–658.
32. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, et al. (1999) The
Banff 97 working classification of renal allograft pathology. Kidney international
55: 713–723.
33. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, et al. (2010) Banff ’09
meeting report: antibody mediated graft deterioration and implementation of
Banff working groups. American journal of transplantation 10: 464–471.
DR
high+CD45RA
2-Tregs in Renal Transplantation
PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e34208